BLA 761090 · Dyax Corp.
Takhzyro
Lanadelumab-Flyo · Subcutaneous · Plasma Kallikrein Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Aug 23, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
20
9 Phase 3, 1 recruiting
FAERS reports
3,228
1,536 serious, 41 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 18, 2026.
TAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older. TAKHZYRO is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older. ( 1 )
Mechanism: Lanadelumab-flyo is a fully human monoclonal antibody (IgG1/κ-light chain) that binds plasma kallikrein and inhibits its proteolytic activity. Plasma kallikrein is a protease that cleaves high-molecular-weight-kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin, a potent vasodilator that increases vascular permeability resulting in swelling and pain associated with HAE. In patients with HAE due to C1-inhibitor (C1-INH) deficiency or dysfunction, normal regulation of plasma kallikrein activity is not present, which leads to uncontrolled increases in plasma kallikrein activity and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 3, 2023 Supplement 10 · Efficacy · priority review OrphanLetterLabel
- Aug 23, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
- TAKHZYRO · LANADELUMAB-FLYO 300MG/2ML (150MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- TAKHZYRO · LANADELUMAB-FLYO 300MG/2ML (150MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lanadelumab" as an intervention, any sponsor and status, largest first.
- Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized PatientsPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT04590586 · 515 participants · Start Nov 24, 2020 · Primary completion Aug 3, 2021
Drug: Standard of care; Apremilast and 5 more · For: COVID-19
Sites: Anniston, Alabama; Bakersfield, California; Chula Vista, California · 59 sites in all
- Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAEPivotal-lookingCompleted
ShireTakeda (TAK)
NCT02741596 · 212 participants · Start May 26, 2016 · Primary completion Oct 31, 2019
Drug: DX-2930; DX-2930 · For: Hereditary Angioedema (HAE)
Sites: Birmingham, Alabama; Scottsdale, Arizona; San Diego, California · 43 sites in all
- A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT03918239 · 190 participants · Start May 14, 2019 · Primary completion Nov 13, 2019
Drug: SHP643 · For: Healthy Volunteers
Sites: Miami, Florida
- Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAEPivotal-lookingCompleted
ShireTakeda (TAK)
NCT02586805 · 125 participants · Start Mar 3, 2016 · Primary completion Apr 13, 2017
Drug: DX-2930 - 300mg/2wk; DX-2930 - 300mg/4wk and 2 more · For: Hereditary Angioedema (HAE)
Sites: Birmingham, Alabama; Scottsdale, Arizona; San Diego, California · 41 sites in all
- A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT04206605 · 77 participants · Start May 4, 2020 · Primary completion Oct 20, 2022
Drug: Lanadelumab · For: Angioedema
Sites: Birmingham, Alabama; Scottsdale, Arizona; San Diego, California · 45 sites in all
- A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-InhibitorPivotal-lookingCompleted
ShireTakeda (TAK)
NCT04444895 · 73 participants · Start Feb 5, 2021 · Primary completion May 5, 2023
Drug: Lanadelumab · For: Angioedema
Sites: Birmingham, Alabama; Scottsdale, Arizona; San Diego, California · 35 sites in all
Radboud University Medical CenterAcademic, hospital or other
NCT04422509 · 43 participants · Start Oct 30, 2020 · Primary completion Feb 25, 2021
Drug: lanadelumab · For: COVID-19
Sites: Amsterdam, Netherlands; Arnhem, Netherlands; Nijmegen, Netherlands · 4 sites in all
ShireTakeda (TAK)
NCT02093923 · 38 participants · Start May 14, 2014 · Primary completion May 18, 2015
Drug: DX-2930; Placebo · For: Hereditary Angioedema (HAE)
Sites: San Diego, California; Walnut Creek, California; Tampa, Florida · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hereditary angioedema1,217
- drug ineffective298
- product dose omission issue265
- weight increased245
- weight decreased238
- headache188
- condition aggravated187
- inappropriate schedule of product administration169
- product use issue161
- intentional product use issue157
- injection site pain143
- stress143
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 106 |
| 2019 | 393 |
| 2020 | 318 |
| 2021 | 291 |
| 2022 | 325 |
| 2023 | 374 |
| 2024 | 474 |
| 2025 | 563 |
| 2026 | 373 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Takhzyro (Lanadelumab-Flyo)
2024 spending
$223M
Beneficiaries
512
4,752 claims
Per beneficiary
$435,556
$12,775.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $151,333,291 |
| 2021 | $174,024,500 |
| 2022 | $192,066,440 |
| 2023 | $194,367,297 |
| 2024 | $223,004,903 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
Banerji A, Riedl MA, Bernstein JA, et al. · JAMA 2018 · Clinical Trial, Phase III, Comparative Study
- Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema.
Walsh S, Bartlett M, Salvo-Halloran EM, et al. · Drugs R D 2025 · Network Meta-Analysis, Systematic Review
- Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
Banerji A, Bernstein JA, Johnston DT, et al. · Allergy 2022 · Clinical Trial, Research Support, Non-U.S. Gov't
- Donidalorsen Treatment of Hereditary Angioedema in Patients Previously on Long-Term Prophylaxis.
Riedl MA, Bernstein JA, Jacobs JS, et al. · J Allergy Clin Immunol Pract 2025 · Clinical Trial, Phase III, Multicenter Study
- Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study.
Maurer M, Lumry WR, Li HH, et al. · J Allergy Clin Immunol Pract 2024 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.
Lumry WR, Weller K, Magerl M, et al. · Allergy 2021 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
Sponsor: Dyax Corp.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.